A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
Cancer Chemotherapy and Pharmacology1999Vol. 44(5), pp. 372–380
Citations Over TimeTop 10% of 1999 papers
David Rinaldi, John G. Kuhn, Howard A. Burris, F. Andrew Dorr, Gladys Rodriguez, S. Gail Eckhardt, Suzanne F. Jones, James R. Woodworth, Sharyn D. Baker, Connie Langley, David Mascorro, Trent Abrahams, Daniel D. Von Hoff
Related Papers
- → Anticancer Antifolates: Current Status and Future Directions(2003)304 cited
- → Antifolate Analogs(1993)42 cited
- Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.(1999)
- Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.(2007)
- [New analogues of methotrexate].(1992)